(lp0
S'Sangamo Therapeutics Announces Presentation of New Data Demonstrating ... PR Newswire  - Mar 29, 2017 RICHMOND, Calif., March 29, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. , the leader in therapeutic genome editing, announced today the presentation of new human in vitro and animal model data demonstrating significant&nbsp;...Biotech Premarket Movers: Vertex, Sangamo, Depomed - TheStreet.comChicago Bridge &amp; Iron. - Active Runners in Experts Views: Sangamo ... - Seneca Globe'
p1
aS"Sangamo Therapeutics Reports Fourth Quarter And Full Year 2016 Financial Results PR Newswire  - Feb 28, 2017 &quot;Early this year we rebranded our company as Sangamo Therapeutics, underscoring our focus on clinical development of genomic therapies using our industry leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy,&quot;&nbsp;...Sangamo BioSciences'  CEO Sandy Macrae on Q4 2016 Results - Earnings ... - Seeking Alpha"
p2
aS'Sangamo BioSciences Changes Name To Sangamo Therapeutics, Underscoring Focus ... PR Newswire  - Jan 6, 2017 RICHMOND, Calif., Jan. 6, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. , the leader in therapeutic genome editing, announces that it has changed its corporate name, from &quot;Sangamo BioSciences, Inc.&quot; to &quot;Sangamo Therapeutics, Inc.&quot;&nbsp;...'
p3
aS'Sangamo Therapeutics Receives Orphan Drug Designation from the FDA for SB-913 ... PR Newswire  - Mar 1, 2017 RICHMOND, Calif., March 1, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. , the leader in therapeutic genome editing, announced today that the U.S.'
p4
aS'Stock Returns: Enanta Pharmaceuticals Inc  versus Sangamo ... CML News - Apr 17, 2017 This is a snapshot to compare the stock returns for Enanta Pharmaceuticals Inc  versus Sangamo Therapeutics Inc  . The stock return points we compare look at the last three-months, six-months and twelve-months.'
p5
aS'Option Market Alert: Sangamo Therapeutics Inc Implied Price Swing Hits An ... CML News - Apr 13, 2017 No Risk Alert Here: Before we dive into any analysis we simply note that Sangamo Therapeutics Inc  risk is neither elevated nor depressed.Cowen and Company Reaffirms &quot;Buy&quot; Rating for Sangamo Therapeutics Inc  - The Cerbat GemAn Inside Look at Trading Hot Stocks: Sangamo Therapeutics, Inc. (SGMO ... - Post Analyst'
p6
aS'Price Alert: Sangamo Therapeutics Inc  Stock Nears Resistance ... CML News - Apr 6, 2017 Price Alert: Sangamo Therapeutics Inc  has now crossed into technical strength -- watch the technical oscillators for momentum gaps.'
p7
aS'Sangamo Therapeutics, Inc.  held by 34 SEC 13F Filers Post Analyst - 21 hours ago Sangamo Therapeutics, Inc.  reached 60.38% versus a 1-year low price of $2.65. The stock was last seen 0% lower, reaching at $4.25 on Apr. 13, 2017.Sangamo Therapeutics Inc  Rating Reiterated by Cowen and Company - BBNSThe Sangamo Therapeutics  Getting Somewhat Positive Press Coverage ... - Petro Global News 24'
p8
aS"Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug ... PR Newswire  - Jan 5, 2017 5, 2017 /PRNewswire/ -- Sangamo BioSciences, Inc.  today announced that the U.S. Food and Drug Administration  has cleared the Company's Investigational New Drug application  for its SB-525 gene therapy program for the treatment ...FDA OKs Sangamo's IND for gene therapy candidate for hemophilia A; shares ... - Seeking Alpha"
p9
aS'SANGAMO THERAPEUTICS, INC.  Files An 8-K Departure of Directors ... Market Exclusive - Mar 20, 2017 On March 14, 2017, the Compensation Committee of the Board of Directors of Sangamo Therapeutics, Inc.  adopted an Executive Severance Plan .'
p10
a.